{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T21:34:29Z","timestamp":1786743269799,"version":"build-2736575974"},"reference-count":61,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T00:00:00Z","timestamp":1786147200000},"content-version":"vor","delay-in-days":7,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2022YFC2304102"],"award-info":[{"award-number":["2022YFC2304102"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82272301"],"award-info":[{"award-number":["82272301"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002367","name":"Chinese Academy of Sciences","doi-asserted-by":"publisher","award":["XDB0490000"],"award-info":[{"award-number":["XDB0490000"]}],"id":[{"id":"10.13039\/501100002367","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Advanced Research"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.jare.2026.08.033","type":"journal-article","created":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T00:40:11Z","timestamp":1786322411000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["A biparatopic antibody targeting the C\u03b52 and C\u03b53 domains of IgE disrupts IgE-Fc\u03b5RI interaction"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8443-6060","authenticated-orcid":false,"given":"Lixia","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peiyi","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingyu","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-6639-4713","authenticated-orcid":false,"given":"Yongshan","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojiao","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxue","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengbing","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhua","family":"Shang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bofeng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1395-188X","authenticated-orcid":false,"given":"Tengchuan","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jare.2026.08.033_b0005","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1056\/NEJM200101043440106","article-title":"Allergy and allergic diseases","volume":"344","author":"Kay","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jare.2026.08.033_b0010","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2023-080612","article-title":"Global, regional and national epidemiology of allergic disorders in children from 1990 to 2019: findings from the Global Burden of Disease study 2019","volume":"14","author":"Lv","year":"2024","journal-title":"BMJ Open"},{"issue":"2023","key":"10.1016\/j.jare.2026.08.033_b0015","first-page":"2232","article-title":"to 2019: a systematic analysis for the Global Burden of Disease Study 2019","volume":"78","author":"Shin","year":"1990","journal-title":"Allergy"},{"key":"10.1016\/j.jare.2026.08.033_b0020","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1146\/annurev-immunol-061020-053712","article-title":"IgE, IgE receptors and Anti-IgE biologics: protein structures and mechanisms of action","volume":"41","author":"McDonnell","year":"2023","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.jare.2026.08.033_b0025","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1067\/mai.2002.126811","article-title":"Anaphylaxis: a review of causes and mechanisms","volume":"110","author":"Kemp","year":"2002","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jare.2026.08.033_b0030","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1038\/nri2273","article-title":"IgE in allergy and asthma today","volume":"8","author":"Gould","year":"2008","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jare.2026.08.033_b0035","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1146\/annurev.immunol.17.1.931","article-title":"The high-affinity IgE receptor (Fc\u03b5RI): from physiology to pathology","volume":"17","author":"Kinet","year":"1999","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.jare.2026.08.033_b0040","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/nri2072","article-title":"New developments in Fc\u03b5RI regulation, function and inhibition","volume":"7","author":"Kraft","year":"2007","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jare.2026.08.033_b0045","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1038\/nature07204","article-title":"The development of allergic inflammation","volume":"454","author":"Galli","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.jare.2026.08.033_b0050","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1038\/nm.2755","article-title":"IgE and mast cells in allergic disease","volume":"18","author":"Galli","year":"2012","journal-title":"Nat Med"},{"key":"10.1016\/j.jare.2026.08.033_b0055","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/35037021","article-title":"Signalling through the high-affinity IgE receptor Fc\u03b5RI","volume":"402","author":"Turner","year":"1999","journal-title":"Nature"},{"key":"10.1016\/j.jare.2026.08.033_b0060","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/S0092-8674(00)81719-5","article-title":"Crystal structure of the human high-affinity IgE receptor","volume":"95","author":"Garman","year":"1998","journal-title":"Cell"},{"key":"10.1016\/j.jare.2026.08.033_b0065","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1038\/337187a0","article-title":"Complete structure and expression in transfected cells of high affinity IgE receptor","volume":"337","author":"Blank","year":"1989","journal-title":"Nature"},{"key":"10.1016\/j.jare.2026.08.033_b0070","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1038\/s41586-024-07864-5","article-title":"Structural insights into the high-affinity IgE receptor Fc\u03b5RI complex","volume":"633","author":"Deng","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.jare.2026.08.033_b0075","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1111\/all.14724","article-title":"The role of CD23 in the regulation of allergic responses","volume":"76","author":"Engeroff","year":"2021","journal-title":"Allergy"},{"key":"10.1016\/j.jare.2026.08.033_b0080","doi-asserted-by":"crossref","first-page":"3199","DOI":"10.4049\/jimmunol.1102689","article-title":"Soluble CD23 controls IgE synthesis and homeostasis in human B cells","volume":"188","author":"Cooper","year":"2012","journal-title":"J Immunol"},{"key":"10.1016\/j.jare.2026.08.033_b0085","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/366421a0","article-title":"The human IgE network","volume":"366","author":"Sutton","year":"1993","journal-title":"Nature"},{"key":"10.1016\/j.jare.2026.08.033_b0090","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1111\/imr.12340","article-title":"Structure and dynamics of IgE-receptor interactions: Fc\u03b5RI and CD23\/Fc\u03b5RII","volume":"268","author":"Sutton","year":"2015","journal-title":"Immunol Rev"},{"key":"10.1016\/j.jare.2026.08.033_b0095","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S1074-7613(00)00037-6","article-title":"Structure of the human IgE-Fc C\u03b53-C\u03b54 reveals conformational flexibility in the antibody effector domains","volume":"13","author":"Wurzburg","year":"2000","journal-title":"Immunity"},{"key":"10.1016\/j.jare.2026.08.033_b0100","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1016\/S0161-5890(02)00035-4","article-title":"Structural insights into the interactions between human IgE and its high affinity receptor Fc\u03b5RI","volume":"38","author":"Wurzburg","year":"2002","journal-title":"Mol Immunol"},{"key":"10.1016\/j.jare.2026.08.033_b0105","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/35018500","article-title":"Structure of the Fc fragment of human IgE bound to its high-affinity receptor Fc epsilonRI alpha","volume":"406","author":"Garman","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.jare.2026.08.033_b0110","doi-asserted-by":"crossref","unstructured":"H. RG, T. P, G. GJ, B. RL, R. R, H. VM, et al., The structure of human CD23 and its interactions with IgE and CD21, The Journal of experimental medicine. 202 (2005) 751-760","DOI":"10.1084\/jem.20050811"},{"key":"10.1016\/j.jare.2026.08.033_b0115","doi-asserted-by":"crossref","unstructured":"B. Dhaliwal, D. Yuan, M. O. Y. Pang, A. J. Henry, K. Cain, A. Oxbrow, et al., Crystal structure of IgE bound to its B-cell receptor CD23 reveals a mechanism of reciprocal allosteric inhibition with high affinity receptor Fc\u03b5RI, Proceedings of the National Academy of Sciences of the United States of America. 109 (2012) 12686-12691.","DOI":"10.1073\/pnas.1207278109"},{"key":"10.1016\/j.jare.2026.08.033_b0120","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1038\/ni811","article-title":"The crystal structure of IgE Fc reveals an asymmetrically bent conformation","volume":"3","author":"Wan","year":"2002","journal-title":"Nat Immunol"},{"key":"10.1016\/j.jare.2026.08.033_b0125","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1038\/nsmb.2795","article-title":"Human immunoglobulin E flexes between acutely bent and extended conformations","volume":"21","author":"Drinkwater","year":"2014","journal-title":"Nat Struct Mol Biol"},{"key":"10.1016\/j.jare.2026.08.033_b0130","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/87603","article-title":"The structure of the IgE C\u03b52 domain and its role in stabilizing the complex with its high-affinity receptor Fc\u03b5Rl\u03b1","volume":"8","author":"McDonnell","year":"2001","journal-title":"Nat Struct Biol"},{"key":"10.1016\/j.jare.2026.08.033_b0135","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1038\/nsmb.2044","article-title":"Conformational changes in IgE contribute to its uniquely slow dissociation rate from receptor Fc\u025bRI","volume":"18","author":"Holdom","year":"2011","journal-title":"Nat Struct Mol Biol"},{"key":"10.1016\/j.jare.2026.08.033_b0140","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-32200-z","article-title":"The Fab fragment of anti-IgE C\u03b52 domain prevents allergic reactions through interacting with IgE-Fc\u03b5RI\u03b1 complex on rat mast cells","volume":"8","author":"Hirano","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.jare.2026.08.033_b0145","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.pharmthera.2018.05.015","article-title":"Approaches to target IgE antibodies in allergic diseases","volume":"191","author":"Balbino","year":"2018","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.jare.2026.08.033_b0150","doi-asserted-by":"crossref","first-page":"2491","DOI":"10.1111\/all.14308","article-title":"Past, present, and future of anti-IgE biologics","volume":"75","author":"Guntern","year":"2020","journal-title":"Allergy"},{"key":"10.1016\/j.jare.2026.08.033_b0155","doi-asserted-by":"crossref","first-page":"3729","DOI":"10.1016\/j.ymthe.2024.08.029","article-title":"Reduction of circulating IgE and allergens by a pH-sensitive antibody with enhanced FcyRIIb binding","volume":"32","author":"Li","year":"2024","journal-title":"Mol Ther"},{"key":"10.1016\/j.jare.2026.08.033_b0160","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms11610","article-title":"Structural basis of omalizumab therapy and omalizumab-mediated IgE exchange","volume":"7","author":"Pennington","year":"2016","journal-title":"Nat Commun"},{"key":"10.1016\/j.jare.2026.08.033_b0165","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/nrd1334","article-title":"Omalizumab","volume":"3","author":"Ames","year":"2004","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.jare.2026.08.033_b0170","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1067\/mai.2001.117880","article-title":"Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma","volume":"108","author":"Busse","year":"2001","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jare.2026.08.033_b0175","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1056\/NEJMoa2312382","article-title":"Omalizumab for the treatment of multiple food allergies","volume":"390","author":"Wood","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jare.2026.08.033_b0180","doi-asserted-by":"crossref","first-page":"2689","DOI":"10.1056\/NEJMct055184","article-title":"Omalizumab for asthma","volume":"354","author":"Strunk","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jare.2026.08.033_b0185","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1056\/NEJMc1305687","article-title":"Omalizumab for chronic urticaria","volume":"368","author":"Wu","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jare.2026.08.033_b0190","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/j.jaci.2016.03.030","article-title":"Anaphylactic reactions associated with omalizumab administration: analysis of a case-control study","volume":"138","author":"Lieberman","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jare.2026.08.033_b0195","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1146\/annurev-biochem-063011-092449","article-title":"Nanobodies: natural single-domain antibodies","volume":"82","author":"Muyldermans","year":"2013","journal-title":"Annu Rev Biochem"},{"key":"10.1016\/j.jare.2026.08.033_b0200","article-title":"Shark nanobodies with potent SARS-CoV-2 neutralizing activity and broad sarbecovirus reactivity","volume":"14","author":"Chen","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.jare.2026.08.033_b0205","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/363446a0","article-title":"Naturally-occurring antibodies devoid of light-chains","volume":"363","author":"Hamerscasterman","year":"1993","journal-title":"Nature"},{"key":"10.1016\/j.jare.2026.08.033_b0210","doi-asserted-by":"crossref","first-page":"4196","DOI":"10.1038\/s41467-025-58669-7","article-title":"A potent protective bispecific nanobody targeting Herpes simplex virus gD reveals vulnerable epitope for neutralizing","volume":"16","author":"Hu","year":"2025","journal-title":"Nat Commun"},{"key":"10.1016\/j.jare.2026.08.033_b0215","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1038\/s41421-022-00497-w","article-title":"A bispecific nanobody dimer broadly neutralizes SARS-CoV-1 & 2 variants of concern and offers substantial protection against Omicron via low-dose intranasal administration","volume":"8","author":"Ma","year":"2022","journal-title":"Cell Discov"},{"key":"10.1016\/j.jare.2026.08.033_b0220","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.576255","article-title":"Nanobodies\u2014Useful Tools for Allergy Treatment?","volume":"11","author":"Flicker","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.jare.2026.08.033_b0225","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2024.2310890","article-title":"Biparatopic antibodies: therapeutic applications and prospects","volume":"16","author":"Niquille","year":"2024","journal-title":"MAbs"},{"key":"10.1016\/j.jare.2026.08.033_b0230","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1146\/annurev-immunol-042617-053327","article-title":"Exploiting nanobodies' singular traits","volume":"36","author":"Ingram","year":"2018","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.jare.2026.08.033_b0235","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1136\/annrheumdis-2013-eular.248","article-title":"Twenty-four weeks of treatment with a novel Anti-IL-6 receptor nanobody\u00ae (ALX-0061) resulted in 84% ACR20 improvement and 58% DAS28 remission in a phase I\/II study in RA","volume":"72","author":"Holz","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jare.2026.08.033_b0240","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s12265-012-9435-y","article-title":"Novel antiplatelet agents: ALX-0081, a nanobody directed towards von willebrand factor","volume":"6","author":"Bartunek","year":"2013","journal-title":"J Cardiovasc Transl Res"},{"key":"10.1016\/j.jare.2026.08.033_b0245","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1056\/NEJMoa1505533","article-title":"Caplacizumab for acquired thrombotic thrombocytopenic purpura","volume":"374","author":"Peyvandi","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jare.2026.08.033_b0250","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1111\/jth.13716","article-title":"Caplacizumab reduces the frequency of major thromboembolic events, exacerbations and death in patients with acquired thrombotic thrombocytopenic purpura","volume":"15","author":"Peyvandi","year":"2017","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jare.2026.08.033_b0255","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa1806311","article-title":"Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura","volume":"380","author":"Scully","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jare.2026.08.033_b0260","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.3389\/fimmu.2017.01361","article-title":"In Vitro maturation of a humanized shark VNAR domain to improve its biophysical properties to facilitate clinical development","volume":"8","author":"Steven","year":"2017","journal-title":"Front Immunol"},{"key":"10.1016\/j.jare.2026.08.033_b0265","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.02438-20","article-title":"Potent neutralization of SARS-CoV-2 by hetero-bivalent alpaca nanobodies targeting the spike receptor-binding domain","volume":"95","author":"Ma","year":"2021","journal-title":"J Virol"},{"key":"10.1016\/j.jare.2026.08.033_b0270","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-019-13815-w","article-title":"The mechanistic and functional profile of the therapeutic anti-IgE antibody ligelizumab differs from omalizumab","volume":"11","author":"Gasser","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.jare.2026.08.033_b0275","doi-asserted-by":"crossref","first-page":"36251","DOI":"10.1074\/jbc.M112.407502","article-title":"An engineered disulfide bond reversibly traps the IgE-Fc3\u22124 in a closed, nonreceptor binding conformation","volume":"287","author":"Wurzburg","year":"2012","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jare.2026.08.033_b0280","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijbiomac.2024.136635","article-title":"A bispecific antibody targeting the Ig domains of Siglec-E displays enhanced antitumor effects","volume":"281","author":"Zhao","year":"2024","journal-title":"Int J Biol Macromol"},{"key":"10.1016\/j.jare.2026.08.033_b0285","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/s41573-024-00896-6","article-title":"The present and future of bispecific antibodies for cancer therapy","volume":"23","author":"Klein","year":"2024","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.jare.2026.08.033_b0290","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1023\/A:1023918206060","article-title":"Construction of an in vitro allergy reaction evaluation system using human leukemia cell lines","volume":"40","author":"Shim","year":"2002","journal-title":"Cytotechnology"},{"key":"10.1016\/j.jare.2026.08.033_b0295","doi-asserted-by":"crossref","unstructured":"C., G., M., Magnusson, J., H\u00e5\u00e5rd, et al., Demonstration of specific high-affinity Fc\u025b-receptors on the human basophil-like leukemia cell line KU812 by flow cytometry, Allergy. (1995)","DOI":"10.1111\/j.1398-9995.1995.tb02485.x"},{"key":"10.1016\/j.jare.2026.08.033_b0300","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/j.jaci.2021.03.050","article-title":"Structure-guided design of ultrapotent disruptive IgE inhibitors to rapidly terminate acute allergic reactions","volume":"148","author":"Pennington","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jare.2026.08.033_b0305","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2025.05.028","article-title":"High-affinity omalizumab variants with optimized disruptive potency prevent anaphylaxis in vivo","volume":"156","author":"Brigger","year":"2025","journal-title":"J Allergy Clin Immunol"}],"container-title":["Journal of Advanced Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S209012322600665X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S209012322600665X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T21:03:01Z","timestamp":1786741381000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S209012322600665X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":61,"alternative-id":["S209012322600665X"],"URL":"https:\/\/doi.org\/10.1016\/j.jare.2026.08.033","relation":{},"ISSN":["2090-1232"],"issn-type":[{"value":"2090-1232","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A biparatopic antibody targeting the C\u03b52 and C\u03b53 domains of IgE disrupts IgE-Fc\u03b5RI interaction","name":"articletitle","label":"Article Title"},{"value":"Journal of Advanced Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jare.2026.08.033","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V. on behalf of Cairo University.","name":"copyright","label":"Copyright"}]}}